P210 Bcr-Abl interacts with the interleukin-3 β(c) subunit and constitutively activates Jak2

Norma Wilson-Rawls, J. Liu, P. Laneuville, R. B. Arlinghaus

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Chronic myelogenous leukemia is a neoplasm of pluripotent hematopoietic cells. Cytokines such as interleukin-3 and granulocyte-macrophage colony-stimulating factor regulate the growth and differentiation of hematopoietic precursors. These cytokines activate two distinct signals to the nucleus. One signal is through the Ras pathway, and the second involves activation of Jak2. We demonstrated that Bcr-Abl co-immunoprecipitates with and constitutively phosphorylates the common β(c) chain of the interleukin-3 (IL-3) and granulocyte-macrophage-macrophage colony-stimulating factor (GM-CSF) receptors. Our data show that formation of this complex leads to the constitutive activation of Jak2. Previously, it has been demonstrated that Bcr-Abl interacts with Grb2 and Shc, which in turn activates the Ras pathway. Thus, Bcr-Abl can activate signalling through both pathways in a factor-independent fashion.

Original languageEnglish (US)
Pages (from-to)428-431
Number of pages4
JournalLeukemia
Volume11
Issue numberSUPPL. 3
StatePublished - 1997
Externally publishedYes

Fingerprint

Interleukin-3
Macrophage Colony-Stimulating Factor Receptors
Cytokines
Hematologic Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Granulocytes
Macrophages
Growth

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Wilson-Rawls, N., Liu, J., Laneuville, P., & Arlinghaus, R. B. (1997). P210 Bcr-Abl interacts with the interleukin-3 β(c) subunit and constitutively activates Jak2. Leukemia, 11(SUPPL. 3), 428-431.

P210 Bcr-Abl interacts with the interleukin-3 β(c) subunit and constitutively activates Jak2. / Wilson-Rawls, Norma; Liu, J.; Laneuville, P.; Arlinghaus, R. B.

In: Leukemia, Vol. 11, No. SUPPL. 3, 1997, p. 428-431.

Research output: Contribution to journalArticle

Wilson-Rawls, N, Liu, J, Laneuville, P & Arlinghaus, RB 1997, 'P210 Bcr-Abl interacts with the interleukin-3 β(c) subunit and constitutively activates Jak2', Leukemia, vol. 11, no. SUPPL. 3, pp. 428-431.
Wilson-Rawls, Norma ; Liu, J. ; Laneuville, P. ; Arlinghaus, R. B. / P210 Bcr-Abl interacts with the interleukin-3 β(c) subunit and constitutively activates Jak2. In: Leukemia. 1997 ; Vol. 11, No. SUPPL. 3. pp. 428-431.
@article{c80b4164d0a1426093c88f5b544ce308,
title = "P210 Bcr-Abl interacts with the interleukin-3 β(c) subunit and constitutively activates Jak2",
abstract = "Chronic myelogenous leukemia is a neoplasm of pluripotent hematopoietic cells. Cytokines such as interleukin-3 and granulocyte-macrophage colony-stimulating factor regulate the growth and differentiation of hematopoietic precursors. These cytokines activate two distinct signals to the nucleus. One signal is through the Ras pathway, and the second involves activation of Jak2. We demonstrated that Bcr-Abl co-immunoprecipitates with and constitutively phosphorylates the common β(c) chain of the interleukin-3 (IL-3) and granulocyte-macrophage-macrophage colony-stimulating factor (GM-CSF) receptors. Our data show that formation of this complex leads to the constitutive activation of Jak2. Previously, it has been demonstrated that Bcr-Abl interacts with Grb2 and Shc, which in turn activates the Ras pathway. Thus, Bcr-Abl can activate signalling through both pathways in a factor-independent fashion.",
author = "Norma Wilson-Rawls and J. Liu and P. Laneuville and Arlinghaus, {R. B.}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "428--431",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - P210 Bcr-Abl interacts with the interleukin-3 β(c) subunit and constitutively activates Jak2

AU - Wilson-Rawls, Norma

AU - Liu, J.

AU - Laneuville, P.

AU - Arlinghaus, R. B.

PY - 1997

Y1 - 1997

N2 - Chronic myelogenous leukemia is a neoplasm of pluripotent hematopoietic cells. Cytokines such as interleukin-3 and granulocyte-macrophage colony-stimulating factor regulate the growth and differentiation of hematopoietic precursors. These cytokines activate two distinct signals to the nucleus. One signal is through the Ras pathway, and the second involves activation of Jak2. We demonstrated that Bcr-Abl co-immunoprecipitates with and constitutively phosphorylates the common β(c) chain of the interleukin-3 (IL-3) and granulocyte-macrophage-macrophage colony-stimulating factor (GM-CSF) receptors. Our data show that formation of this complex leads to the constitutive activation of Jak2. Previously, it has been demonstrated that Bcr-Abl interacts with Grb2 and Shc, which in turn activates the Ras pathway. Thus, Bcr-Abl can activate signalling through both pathways in a factor-independent fashion.

AB - Chronic myelogenous leukemia is a neoplasm of pluripotent hematopoietic cells. Cytokines such as interleukin-3 and granulocyte-macrophage colony-stimulating factor regulate the growth and differentiation of hematopoietic precursors. These cytokines activate two distinct signals to the nucleus. One signal is through the Ras pathway, and the second involves activation of Jak2. We demonstrated that Bcr-Abl co-immunoprecipitates with and constitutively phosphorylates the common β(c) chain of the interleukin-3 (IL-3) and granulocyte-macrophage-macrophage colony-stimulating factor (GM-CSF) receptors. Our data show that formation of this complex leads to the constitutive activation of Jak2. Previously, it has been demonstrated that Bcr-Abl interacts with Grb2 and Shc, which in turn activates the Ras pathway. Thus, Bcr-Abl can activate signalling through both pathways in a factor-independent fashion.

UR - http://www.scopus.com/inward/record.url?scp=0030843270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030843270&partnerID=8YFLogxK

M3 - Article

C2 - 9209414

AN - SCOPUS:0030843270

VL - 11

SP - 428

EP - 431

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - SUPPL. 3

ER -